Amundi
KLRS

Amundi’s Kalaris Therapeutics KLRS Stock Holding History

Amundi’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,976
Closed -$36K – 2204
2024
Q3 		$36K Buy
+1,976
New +$34.6K ﹤0.01% 1869
2024
Q2 		– Sell
-1,976
Closed -$33.7K – 2068
2024
Q1 		$33.7K Hold
1,976
– – ﹤0.01% 1877
2023
Q4 		$30.9K Buy
+1,976
New +$77.9K ﹤0.01% 1923
2021
Q4 		– Sell
-64
Closed -$37K – 1726
2021
Q3 		$37K Buy
+64
New +$29.6K ﹤0.01% 1540

Other funds holding KLRS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amundi's KLRS Position: Q4 2024 in Review

Amundi sold out of Kalaris Therapeutics (KLRS) in Q4 2024, closing a stake of 1,976 shares — an estimated $36K sold.

Amundi first reported a position in KLRS in Q3 2021 and held it in 4 quarters. The position peaked at $37K in Q3 2021. 52 funds tracked by Wall St. Rank hold KLRS as of Q4 2024.

  • Amundi reported no remaining Kalaris Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Amundi sold 1,976 Kalaris Therapeutics shares in Q4 2024, an estimated $36K.
  • Amundi first reported a position in Kalaris Therapeutics in Q3 2021 and held it in 4 quarters.
  • Amundi's Kalaris Therapeutics position peaked at $37K in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2024.

Based on Amundi's 13F filing for Q4 2024, filed 7 Feb 2025.